CXCL8 and non-small cell lung carcinoma: A large study in 1344 advanced cancer patients treated with nivolumab and/or ipilimumab, everolimus, or docetaxel, which included 363 NSCLC patients (squamous NSCLC, n = 108, from CheckMate 017; nonsquamous NSCLC, n = 255, from CheckMate 057), demonstrated that elevated serum IL-8 at baseline associated with poor outcome across treatment and cancer types [30].